ReviewImmunologic research2005
Regulatory T cell-mediated transplantation tolerance.
Review in Immunologic research, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Association between anti-endothelial antigen antibodies and allograft rejection in kidney transplantation.Journal of clinical laboratory analysis · 2023Article
- Increased Autoantibodies Against Ro/SS-A, CENP-B, and La/SS-B in Patients With Kidney Allograft Antibody-mediated Rejection.Transplantation direct · 2021Article
- Carbamylated erythropoietin regulates immune responses and promotes long-term kidney allograft survival through activation of PI3K/AKT signaling.Signal transduction and targeted therapy · 2020Article
- Clinical relevance of lung-restricted antibodies in lung transplantation.Human immunology · 2019Review
- Lung Injury and Loss of Regulatory T Cells Primes for Lung-Restricted Autoimmunity.Critical reviews in immunology · 2017Review
- Interplay between immune responses to HLA and non-HLA self-antigens in allograft rejection.Human immunology · 2013Review
- Critical role for IL-17A/F in the immunopathogenesis of obliterative airway disease induced by Anti-MHC I antibodies.Transplantation · 2013Article
- Role of antibodies to self-antigens in chronic allograft rejection: potential mechanism and therapeutic implications.Human immunology · 2012Review
- A shift in the collagen V antigenic epitope leads to T helper phenotype switch and immune response to self-antigen leading to chronic lung allograft rejection.Clinical and experimental immunology · 2012Article
- Alloimmunity and autoimmunity in chronic rejection.Current opinion in organ transplantation · 2010Review
- Characterization of virus-specific T-cell immunity in liver allograft recipients with HCV-induced cirrhosis.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2008Article
- Allopeptides and the alloimmune response.Cellular immunology · 2007Review
- Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling.The Journal of clinical investigation · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The existence of naturally occurring regulatory T cells in normal hosts and their pivotal role in maintaining both auto- and allo-tolerance have direct implications on the therapy of autoimmune disorders and for achieving immunosuppression-free allotransplantation. Among the various forms of regulatory T cells described, CD4(+)CD25(+) T cells have emerged as one of the most potent tolerogenic subsets. In this review, we discuss the molecular basis of development and function of these regulatory T cells and their potential role in the context of chronic lung allograft rejection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.